Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fratino, Lucia
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2	Recruiting	3	700	Europe, Canada, US, RoW	disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin	Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC	Urothelial Carcinoma	06/26	04/29
RAPSON, NCT03230734 / 2016-004452-29: Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer	Active, not recruiting	2	70	Europe	Radium-223, Docetaxel	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Bayer	Metastatic Castration-resistant Prostate Cancer	07/25	07/25
NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma	Recruiting	N/A	1000	Europe	Active systemic or non-systemic treatment (palliative or observation procedure)	Federation of Italian Cooperative Oncology Groups	Carcinoma, Urothelial	11/25	11/25
Borsatti, Eugenio
RAPSON, NCT03230734 / 2016-004452-29: Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer	Active, not recruiting	2	70	Europe	Radium-223, Docetaxel	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Bayer	Metastatic Castration-resistant Prostate Cancer	07/25	07/25